PremiumThe FlyGrace Therapeutics files to sell 8.84M shares of common stock for holders Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating Grace Therapeutics reports Q3 EPS (36c), consensus (46c) PremiumCompany AnnouncementsGrace Therapeutics Reports Steady Progress and Financials Grace Therapeutics reports Q2 EPS (30c) vs (43c) last year ACST Earnings Report this Week: Is It a Buy, Ahead of Earnings? PremiumThe FlyGrace Therapeutics to host virtual KOL event on GTX-104 
